193 related articles for article (PubMed ID: 34607937)
21. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
23. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
24. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
[TBL] [Abstract][Full Text] [Related]
25. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
26. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
27. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
28. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer.
Pingili AK; Chaib M; Sipe LM; Miller EJ; Teng B; Sharma R; Yarbro JR; Asemota S; Al Abdallah Q; Mims TS; Marion TN; Daria D; Sekhri R; Hamilton AM; Troester MA; Jo H; Choi HY; Hayes DN; Cook KL; Narayanan R; Pierre JF; Makowski L
Cell Rep; 2021 Jun; 35(12):109285. PubMed ID: 34161764
[TBL] [Abstract][Full Text] [Related]
30. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
31. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
32. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
33. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
34. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
[TBL] [Abstract][Full Text] [Related]
35. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
[TBL] [Abstract][Full Text] [Related]
36. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
[TBL] [Abstract][Full Text] [Related]
37. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
Pedros C; Canonigo-Balancio AJ; Kong KF; Altman A
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212947
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
40. Induced regulatory T cells in inhibitory microenvironments created by cancer.
Whiteside TL
Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]